Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
63rd Annual Meeting of the Canadian Urological Association
5-alpha Reductase Inhibitors in Prostate Cancer Prevention: The PCPT Revisited
Edmonton, Alberta / June 22-25, 2008
Edmonton - The PCPT (Prostate Cancer Prevention Trial) was a large independent randomized trial designed to answer whether long-term treatment with the 5-alpha reductase inhibitor (5ARI) finasteride could prevent prostate cancer in men ³55...
ABSTRACTS in PERSPECTIVE based on presentations from the 10th International Conference on Malignant Lymphoma
Follicular Lymphoma: A Heterogeneous Disease with Improving Prognosis - Editorial Overview: Dr. Joseph Connors / New Perspectives in the Treatment of Aggressive B-Cell Lymphomas - Editorial Overview: Dr. Michael Crump
Lugano, Switzerland / June 4-7, 2008
EDITORIAL OVERVIEW: Joseph Connors, MD, ABIM, FRCPC Chair, Lymphoma Tumour Group, BC Cancer Agency, Clinical Professor of Medicine, University of British Columbia, Vancouver, British Columbia Follicular lymphoma (FL) represents the most...
44th Annual Meeting of the American Society of Clinical Oncology
Updated Anti-emetic Regimens Reduce Emesis Risk from Cisplatin to Carboplatin Levels: Patients Benefit from Survival Advantage
Chicago, Illinois / May 30-June 3, 2008
Chicago - A small but significant survival advantage has been demonstrated for cisplatin in regimens used for the treatment of a number of malignancies, including non-small-cell lung cancer. In actual practice, physicians often avoid using...
44th Annual Meeting of the American Society of Clinical Oncology
Manipulating Active Therapies to Prolong Survival in Brain Malignancies: Phase II and III Study Results
Chicago, Illinois / May 30-June 3, 2008
Chicago - New data from phase II and III studies have documented incremental progress in the management of common brain malignancies from the standpoint of both efficacy and tolerability. In a multicentre trial conducted in Canada,...
ABSTRACTS IN PERSPECTIVE based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
The Role of mTOR in Cancer Etiology and Treatment
Chicago, Illinois / May 30-June 3, 2008
EDITORIAL OVERVIEW: Mary MacKenzie, MD, FRCPC Division of Medical Oncology, London Health Sciences Centre, Assistant Professor of Medicine, University of Western Ontario, London, Ontario Activation of the PI3/akt/mTOR (mammalian target...
ABSTRACTS IN PERSPECTIVE based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Advanced Hepatocellular and Renal Cell Carcinomas: Updated Data in Specific Patient Populations
Chicago, Illinois / May 30-June 3, 2008
EDITORIAL OVERVIEW: Yoo-Joung Ko, MD, MMSc, SM, FRCPC Division of Hematology/Medical Oncology, Sunnybrook Health Sciences, Centre, Toronto, Ontario The landmark SHARP (Sorafenib HCC Assessment Randomized Protocol) study presented at ASCO...
103rd Annual Meeting of the American Urological Association
Paradigm Shift in the Primary Prevention of Prostate Cancer: Reanalysis of the PCPT Data
Orlando, Florida / May 17-22, 2008
Orlando - Approximately 200,000 men are diagnosed with prostate cancer in the US annually and over 90% of them receive treatment for it. Reducing the frequency of diagnosed cancer could spare a substantial proportion the consequences of...
6th European Breast Cancer Conference
New Treatment Standards in HER2-positive Early Breast Cancer
Berlin, Germany / April 15-19, 2008
Berlin - Treatment advances for breast cancer in the last decades, including endocrine therapy with aromatase inhibitors and chemotherapy with taxanes, have spearheaded reductions in mortality. Yet breast cancer remains the most common...
6th European Breast Cancer Conference
Novel Formulation an Improved Breast Cancer Treatment Option
Berlin, Germany / April 15-19, 2008
Berlin - Taxanes have become well known for their significant activity against metastatic breast cancer (MBC) and other solid tumours. However, the polyoxyethylated castor oil (CrEL) and ethanol solvents needed to emulsify paclitaxel, and...